Evaluation of Musculoskeletal System Symptoms and Biochemical Parameters in COVID-19

Covid19 Clinical Trial

Official title:

Evaluation of Pain Symptoms Correlation With Biochemical and Radiological Findings in COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04780555
• Other study ID #: AIBU-FTR-EY-02
• Status: Completed
• Start date: March 1, 2021
• Est. completion date: August 1, 2021

Study information

• Verified date: August 2021
• Source: Abant Izzet Baysal University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The neutrophil-lymphocyte ratio (NLR) used to demonstrate inflammatory status in recent years can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests.

Description:

Dysregulation in immune responses has been reported in association with hyperinflammation in COVID-19 patients, NLR has been linked to the severity of the patient's clinical status, and an increase in NLR is reported to be an independent risk factor for in-hospital mortality. Pain is a frequently seen symptom at the onset of viral infections and throughout the course of the disease. Although the pain mechanisms triggered by viral pathogens are not yet entirely understood, pain is thought to arise as a result of direct activation of nociceptor neurons by pathogens and their interaction with molecular ligands. Toll-like receptor 7 (TLR7), a pathogen recognition receptor that plays an important role in immune responses to viruses by binding to viral RNA, is known to be involved in pain development in different RNA virus infections. Park et al. showed that extracellular micro RNAs activate nociceptive neurons via the TLR7 pathway. Although these mechanisms have been demonstrated for different viral infections, the viral pathogenesis leading to pain in COVID-19 is still unclear. The purpose of this study was to investigate the prevalence of headache and muscular pain in patients diagnosed with COVID-19 and to determine the relationship between these symptoms and inflammatory parameters.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: August 1, 2021
• Est. primary completion date: July 25, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Aged 18-70

• Diagnosed with COVID-19

Exclusion Criteria:

• Patients with suspected SARS-CoV-2 infection, with two negative RT-PCR tests, hospitalized in the intensive care unit during inclusion in the study

• Musculoskeletal pains in the previous three months, with diseases capable of causing myalgia prior to diagnosis (such as fibromyalgia and inflammatory muscle disease)

• Cognitive disorders capable of preventing history-taking and physical examination such as mental disability and dementia,

• previous history of headache (migraine, tension type headache)

Related Conditions & MeSH terms

• Covid19

Locations

Country	Name	City	State
Turkey	Elif Yaksi	Merkez	Bolu

Sponsors (1)

Lead Sponsor	Collaborator
Abant Izzet Baysal University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neutrophil-lymphocyte ratio (NLR)	It can be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count at routine blood tests	Baseline
Primary	D-dimer	Peripheral venous blood specimens were collected using standard surgical procedures	Baseline
Primary	Fibrinogen	Peripheral venous blood specimens were collected using standard surgical procedures	Baseline